Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 28, 2026 09:30 ET | Source: Stemline Therapeutics, Inc.

Menarini Group Presents New Data from the Phase 1b/2 ELEVATE Study of Elacestrant (ORSERDU®) in Combination with Capivasertib in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

Encouraging safety and preliminary efficacy analysis from the elacestrant and capivasertib Phase 1b regimen of the ELEVATE study will be presented.The efficacy data highlight how the combination of...